Overview A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD Status: COMPLETED Trial end date: 2023-05-29 Target enrollment: Participant gender: Summary To evaluate the efficacy and safety of HL231 Solution for Inhalation vs Ultibro in Chinese patients with moderate to severe COPD.Phase: PHASE2 Details Lead Sponsor: Haisco Pharmaceutical Group Co., Ltd.